
West Nile - Pipeline Insight, 2024
Description
West Nile - Pipeline Insight, 2024
DelveInsight’s, “West Nile - Pipeline Insight, 2024,” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in West Nile pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
West Nile: Overview
The West Nile virus is an enveloped, single-stranded RNA arbovirus that can cause disease in humans. These range from the asymptomatic infected patient to fever and malaise to florid neurological deficits secondary to encephalitis and neuroinvasive disease. It is known to cause disease in humans with a wide array of presentations. These range from the asymptomatic infected patient to fever and malaise to florid neurological deficits secondary to encephalitis. However, most people infected with West Nile virus are asymptomatic. Approximately 1 in 4 patients experience fever with symptoms of a viral syndrome, while around 1 in 200 develops neuroinvasive disease. The West Nile virus infects humans following a mosquito bite. The Culex species of mosquito is the most common vector. Besides humans, the West Nile virus can infect birds, horses, dogs, and many other mammals. Wild birds may be the optimal hosts for harboring and enabling amplification of the virus. Humans are considered accidental dead-end hosts due to the low and transient viral levels in the bloodstream. Additional and rare means of transmission include infected donor blood, organs, breast milk, or transplacental infection.
Routine labs may reveal leukocytosis and other non-specific findings secondary to the viral infection. The diagnosis is via serologic detection of West Nile virus using an enzyme-linked immunosorbent assay (ELISA) for the IgM antibody in blood or CSF samples. A plaque reduction neutralization test (PRNT) can distinguish serologic cross-reactions. Treatment of West Nile virus is primarily supportive care. Researchers have tried several agents including interferon, ribavirin, and intravenous immunoglobulin. No clear efficacy data exists as only one controlled study has been performed to date.
""West Nile - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the West Nile pipeline landscape is provided which includes the disease overview and West Nile treatment guidelines. The assessment part of the report embraces, in depth West Nile commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, West Nile collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- In May 2020, Orgenesis launched its new cell-based vaccine platform targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, as well as other viral diseases such as Zika, West Nile Virus, Yellow Fever, Dengue Fever, MERS, HCV and Cytomegalovirus infection (CMV).
This segment of the West Nile report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
West Nile Emerging Drugs
- West Nile virus vaccine: Najit technologies
- Research programme infectious diseases therapeutics: Plex Pharmaceuticals
Further product details are provided in the report……..
West Nile: Therapeutic Assessment
This segment of the report provides insights about the different West Nile drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in West Nile
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
- Molecule Type
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
- Product Type
West Nile: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses West Nile therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging West Nile drugs.
West Nile Report Insights
- West Nile Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing West Nile drugs?
- How many West Nile drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of West Nile?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the West Nile therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for West Nile and their status?
- What are the key designations that have been granted to the emerging drugs?
- Najit Technologies
- Ennaid Therapeutics
- Hawaii Biotech
- Plex Pharmaceuticals
- Protinhi Therapeutics
- Innovation Pharmaceuticals
- NanoViricides
- Orgenesis
- West Nile virus vaccine
- ETxR12
- HBV 002
- Research programme infectious diseases therapeutics
- Research programme: Flavivirus infections therapeutics
- Brilacidin
- Research programme: antiviral vaccines
Table of Contents
60 Pages
- Introduction
- Executive Summary
- West Nile: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- West Nile – DelveInsight’s Analytical Perspective
- Mid Stage Products (Phase II)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- West Nile virus vaccine: Najit technologies
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Comparative Analysis
- Research programme infectious diseases therapeutics: Plex Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- West Nile Key Companies
- West Nile Key Products
- West Nile- Unmet Needs
- West Nile- Market Drivers and Barriers
- West Nile- Future Perspectives and Conclusion
- West Nile Analyst Views
- West Nile Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.